
OMass closes $310m oversubscribed financing round
Biotechnology company OMass Therapeutics has raised $310 million as part of an oversubscribed Series C financing round. The funding will be used to support the advancement of the company’s lead programme into Phase II clinical development. The company’s lead compound, OMS1620, is a potential best-in-class MC2 (melanocortin-2) receptor antagonist targeting congenital… Read More



